-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C1ooJZ2wzJn2+uIh6ObmEnwG9ACOmcsiols805vClgM4TgbqtZThazL9btbYBizh GUFjjT2ocYKNCKiUynd26g== 0000062391-99-000008.txt : 19991223 0000062391-99-000008.hdr.sgml : 19991223 ACCESSION NUMBER: 0000062391-99-000008 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991222 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALBANY MOLECULAR RESEARCH INC CENTRAL INDEX KEY: 0001065087 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 141742717 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-57327 FILM NUMBER: 99779392 BUSINESS ADDRESS: STREET 1: 21 CORPORATE CIRCLE CITY: ALBANY STATE: NY ZIP: 12202-5154 BUSINESS PHONE: 5184640279 MAIL ADDRESS: STREET 1: 21 CORPORATE CIRCLE1 CITY: ALBANY STATE: NY ZIP: 12203-5154 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G 1 SCHEDULE 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Albany Molecular Research, Inc. --------------------------------------- (Name of Issuer) COMMON STOCK, $.01 PAR VALUE --------------------------------------------------------------------------- (Title of Class of Securities) 012423 10 9 ----------------- (CUSIP Number) December 15, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ x ] Rule 13d-1(d) =========================================================================== Page 1 of 9 Exhibit Index is located at page 8 2 CUSIP No. 012423 10 9 - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 1,627,231 Number of __________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by _________________________________________________________ Each Reporting 7) Sole Dispositive Power 1,627,231 Person With ______________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 1,627,231 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 11.2% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 3 CUSIP No. 012423 10 9 13G - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 1,627,231 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by _________________________________________________________ Each Reporting 7) Sole Dispositive Power 1,627,231 Person With ______________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 1,627,231 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 11.2% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 4 CUSIP No. 012423 10 9 13G This Statement on Schedule 13G (the "Schedule 13G") with respect to the Common Stock of Albany Molecular Research, Inc. (the "Issuer"), is filed jointly by Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to reflect the ownership by API (and deemed beneficial ownership by Pharma) of Common Stock of Albany Molecular Research, Inc. API acquired its interest in Albany Molecular Research before the issuer had a class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, and thus is not required to file this Statement until 45 days after the end of calendar year 1999 pursuant to Rule 13d-1(d). This Schedule is being filed at this time to reflect a change in the ultimate parent of API and Pharma, which occurred December 15, 1999. ITEM 1(a). NAME OF ISSUER: - -------------- - ----------------------- Albany Molecular Research, Inc. ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: - -------------- ------------------------------------------------------------- 21 Corporate Circle Albany, NY 12203-5154 ITEM 2(a). NAME OF PERSON FILING: - ------------- ------------------------------------- Aventis Pharmaceuticals Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ------------- ------------------------------------------------------------- Aventis Pharmaceuticals Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - -------------- ------------------ Delaware As To Both Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. ITEM 2(d). TITLE OF CLASS OF SECURITIES: - -------------- --------------------------------------------- Common Stock, $.01 Par Value 5 CUSIP No. 012423 10 9 13G ITEM 2(e): CUSIP NUMBER: - -------------- ----------------------- 012423 10 9 ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR 13D-2(b): - ---------- ------------------------------------------------------------- Not Applicable ITEM 4. OWNERSHIP: - ---------- ------------------- (a): AMOUNT BENEFICIALLY OWNED: As Of 11/10/99 1,627,231 Shares Of Common Stock. (b): PERCENT OF CLASS: 11.2% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 1,627,231 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 1,627,231 (iv) Shared power to dispose or to direct the disposition of: 0 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - ---------- -------------------------------------------------------------- Not Applicable 6 CUSIP No. 012423 10 9 13G ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. - ----------- ---------------------------------------------------------------- Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH - ---------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY - ------------------------------------------------------------------------------- Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP - ---------- ------------------------------------------------------------- Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. - ---------- --------------------------------------------------- Not Applicable ITEM 10. CERTIFICATION. - ----------- ----------------------- Not Applicable 7 CUSIP No. 012423 10 9 13G SIGNATURES ------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden - --------------------------------- -------------------------- Rebecca R. Tilden Vice President and Secretary After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Assistant Secretary 8 CUSIP No. 012423 10 9 13G EXHIBIT INDEX Exhibit No. Description Page No. - -------------- ------------ --------- 99.A Agreement to File Jointly dated December 9 22, 1999, by and between Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. 9 CUSIP No. 012423 10 9 13G EXHIBIT 99.A AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden - --------------------------------- -------------------------- Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Assistant Secretary -----END PRIVACY-ENHANCED MESSAGE-----